Skip to main content

SphingoTec - The Biomarker Company 

Innovative diagnostic solutions for acute and critical care conditions

The Biomarker Company

SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements into routine clinical practice. We develop biomarkers addressing diagnostically underserved critical care conditions such as acute kidney injury, sepsis, and acute heart failure. First and foremost, our portfolio of tests supports better management of critically ill patients, where fast and reliable information is of the essence in taking treatment decisions.

Our Mission

To improve patient outcomes with innovative diagnostic solutions for acute and critical care.
Actionable insights in real-time.

Certified Quality

SphingoTec is committed to providing products that meet and exceed customer and regulatory requirements.
We produce our products in accordance with EN ISO 13485:2016. 

ISO 13485 Certificate (English)      ISO 13485 Certificate (German)

Innovative biomarkers

Human kidney cross section on blue, science background.

Kidney function biomarker

Proenkephalin A 119-159 (penKid)

The limitations of the current standard of care diagnostics for acute kidney injury are well known, thus is the need to implement new biomarkers to assist better management of acute kidney injury. Timely information on kidney function is crucial to early initiate and adapt renal replacement therapy and nephro-protective strategies 

Three dimensional illustration of blood vessel with flowing erythrocytes and leukocytes.

Endothelial function biomarker

Bioactive adrenomedullin 1-52 (bio-ADM)

Endothelial dysfunction is a hallmark of many acute and critical care conditions, such as sepsis and acute heart failure. Loss of endothelial function causes the formation of edema, shock, and subsequent organ failure.

Headquarter in Hennigsdorf, Germany

SphingoTec is a privately held company with a long history of biomarker discovery, development, and validation. We are the legal manufacturer of CE IVD microtiter plate (MTP) assays. Committed to providing solutions that meet and exceed customer and regulatory requirements, we manufacture our products in accordance with EN ISO 13485:2016.

Learn more about our team

Diagnostic platforms

Close-up of multichannel pipette pipetting into microtiter plate in laboratory.

Microtiter plate assay

The innovative biomarkers are available as CE IVD microtiter plate (MTP) assays. The MTP is a standard tool in analytical research and laboratories. It is a high throughput solution, allowing the measurement of 41 patient samples at once. SphingoTec’s MTP assays are based on a chemiluminescence sandwich immunoassay technology.



SphingoTec receives the certificate being compliant with IVDR (EU) 2017/746.


First licensing agreement for penKid closed with Boditech Med, Inc.


SphingoTec is ISO 13485:2016 certified.


The novel biomarkers are introduced in routine measurements in European university hospitals.


Over 80,000 patients have been measured with our biomarker tests.


SphingoTec enters market by deploying the novel biomarkers via a point-of-care solution and distribution network. 


Financing round: 25 million euro growth capital. Investors: HBM, Wellington Partners, and ILB.


CE-IVD microtiter plate tests for penKid and bio-ADM launched.

2011 - 2013

Bio-ADM and penKid product development. First clinical validation.

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now